Tirzepatide

• To buy with a card: https://hobejim.net/product/ a-tirzepatide /

• every 7 days.

• Starting research dose of 2.5mg for the first 4 weeks.

• Increase research dose to 5mg in week 5.

• Option to increase research dose 2.5mg-5mg every 4-6 weeks as needed.

• Do not research dose higher than 15mg.

Tirzepatide — Dual Incretin (GLP-1 + GIP) Receptor Agonist

Tirzepatide is a long-acting peptide that activates both the GLP-1 and GIP receptors. In research, it’s used to study how dual-incretin signaling influences glucose control, appetite pathways, and body-composition trends beyond what single-pathway GLP-1 analogues show.

Identifiers

CAS: 2023788-19-2

Peptide class: Long-acting incretin analogue (dual GLP-1/GIP)

Approx. MW: ~4.8 kDa (sequence/salt form dependent)

Design: Modified incretin sequence with a fatty-diacid side chain for albumin binding (extended half-life)

How It Works (Plain English)

GLP-1 receptor : supports insulin release, slows gastric emptying, and promotes a natural sense of fullness.

GIP receptor : complements GLP-1 by modulating insulin secretion and adipose signaling in a context-dependent way.

Together : Dual activation lets researchers observe broader metabolic effects than with GLP-1 alone, including changes in energy intake and fat distribution.

Why Researchers Use It

• To compare dual-pathway vs single-pathway incretin signaling.

• To examine glucose tolerance, appetite regulation, and lipid markers .

• To explore body-composition shifts (including visceral fat) over longer time frames.

Key Studies — What Was Tested, What Changed, Why It Matters

Glucose control and insulin dynamics

What was tested: Time-course effects on fasting and post-meal glucose, insulin secretion, and insulin sensitivity.